Novavax | NVAX - Cost Of Sales


Novavax reported $22.1M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Adma Biologics USD 50.4M 8.24M Dec/2025
Agenus USD 642K 399K Sep/2025
AstraZeneca USD 3.27B 471M Dec/2025
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Cassava Sciences USD 3.96M 1.16M Sep/2025
Geron USD 1.31M 263K Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
MannKind USD 33.65M 13.44M Dec/2025
Merck USD 3.32B 531M Dec/2025
Minerva Neurosciences 386K 31K Jun/2024
Moderna USD 452M 245M Dec/2025
Novartis USD 3.54B 7M Dec/2025
Novavax USD 22.1M 608K Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Sanofi EUR 4.29B 421M Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
TG Therapeutics USD 38.14M 10.05M Dec/2025